High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients

Douglas E. Gladstone, Marc G. Golightly, Thomas H. Brannagan

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Introduction: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown. Method: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. Results: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated. Discussion: Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.

Original languageEnglish (US)
Pages (from-to)121-126
Number of pages6
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - Oct 2007
Externally publishedYes


  • CD4RA+
  • CD4RO+
  • Chronic inflammatory demyelinating polyneuropathy
  • High dose cyclophosphamide
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients'. Together they form a unique fingerprint.

Cite this